search
Back to results

A Study of Population and Sex-specific Troponin Cutoffs for Ruling Out Acute Myocardial Infarction (DANSPOT)

Primary Purpose

Coronary Syndrome, Acute, Coronary Artery Disease, Myocardial Infarction

Status
Recruiting
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Implementation of the new population and sex-specific 99th percentile URL for cardiac troponin
Sponsored by
Herlev Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Coronary Syndrome, Acute focused on measuring coronary syndrome, myocardial infarction, clinical assessment, biomarker, troponin

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

- Suspicion of MI and a measurement of troponin

Exclusion Criteria:

  • Age < 18 years

Sites / Locations

  • Hospital of Southern JutlandRecruiting
  • Aalborg University HospitalRecruiting
  • Aarhus University HospitalRecruiting
  • Bispebjerg & Frederiksberg Hospital
  • Rigshospitalet (Blegdamsvej)Recruiting
  • Sydvestjysk Sygehus
  • Glostrup University HospitalRecruiting
  • Gødstrup Regional HospitalRecruiting
  • Herlev & Gentofte HospitalRecruiting
  • C Torp-PedersenRecruiting
  • North Denmark Regional HospitalRecruiting
  • Holbaek Sygehus
  • Horsens HospitalRecruiting
  • Amager & Hvidovre Hospital
  • Sygehus Lillebælt (Kolding Sygehus & Vejle Sygehus)
  • Zealand University Hospital
  • Nykøbing Falster County HospitalRecruiting
  • Odense University HospitalRecruiting
  • Randers Regional Hospital
  • Slagelse Sygehus
  • Svendborg HospitalRecruiting
  • Central Jutland Regional Hospital (Viborg Hospital & Silkeborg Hospital)

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Active Comparator

Arm Label

Control Arm - Current sex-uniform manufacturer provided 99th percentile URL of troponin

Intervention Arm - New population and sex-specific 99th percentile URLs of troponin

Arm Description

Standard use of the current sex-uniform manufacturer provided 99th percentile URL of troponin is utilized at Danish hospitals as a diagnostic cutoff for acute MI for both men and women

Implementation of the new population and sex-specific 99th percentile URLs of troponin for the specific assay utilized at the enrolled centers.

Outcomes

Primary Outcome Measures

A composite of myocardial infarction, unplanned revascularisation (after index admission) or all cause mortality within 1 year of first admission for the primary cohort.
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period. Primary cohort is defined as the cohort of women and men with suspected acute coronary syndrome (ACS) with at least two cTn measurements within 24 hours with a maximal cTn level between the current sex-uniform manufacturer-derived 99th percentiles of cTn and the newly defined sex-specific 99th percentiles for women and men.

Secondary Outcome Measures

Number of women with coronary events in the primary cohort (after index admission)
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period. Primary cohort is defined as the cohort of women and men with suspected acute coronary syndrome (ACS) with at least two cTn measurements within 24 hours with a maximal cTn level between the current sex-uniform manufacturer-derived 99th percentiles of cTn and the newly defined sex-specific 99th percentiles for women and men. Coronary events are defined as the prevalence of cardiovascular death, myocardial infarction or unplanned revascularisation (after index admission) within 1 year of first admission.
Number of men with coronary events in the primary cohort (after index admission)
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period. Primary cohort is defined as the cohort of women and men with suspected acute coronary syndrome (ACS) with at least two cTn measurements within 24 hours with a maximal cTn level between the current sex-uniform manufacturer-derived 99th percentiles of cTn and the newly defined sex-specific 99th percentiles for women and men. Coronary events are defined as the prevalence of cardiovascular death, myocardial infarction or unplanned revascularisation (after index admission) within 1 year of first admission.
Number of women and men with coronary events in the primary cohort (after index admission)
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period. Primary cohort is defined as the cohort of women and men with suspected acute coronary syndrome (ACS) with at least two cTn measurements within 24 hours with a maximal cTn level between the current sex-uniform manufacturer-derived 99th percentiles of cTn and the newly defined sex-specific 99th percentiles for women and men. Coronary events are defined as the prevalence of cardiovascular death, myocardial infarction or unplanned revascularisation (after index admission) within 1 year of first admission.
Number of women diagnosed with acute MI (after index admission)
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
Number of women diagnosed with acute MI
Time frame starts from beginning of index admission, defined as first admission in the study period.
Number of men diagnosed with acute MI (after index admission)
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
Number of men diagnosed with acute MI
Time frame starts from beginning of index admission, defined as first admission in the study period.
The overall number of women and men diagnosed with acute MI (after index admission)
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
The overall number of women and men diagnosed with acute MI
Time frame starts from beginning of index admission, defined as first admission in the study period.
Number of women receiving unplanned revascularization (after index admission)
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period. Revascularization is defined as Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting.
Number of women receiving revascularization
Time frame starts from beginning of index admission, defined as first admission in the study period. Revascularization is defined as Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting.
Number of men receiving unplanned revascularization (after index admission)
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period. Revascularization is defined as Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting.
Number of men receiving revascularization
Time frame starts from beginning of index admission, defined as first admission in the study period. Revascularization is defined as Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting.
The overall number of women and men receiving unplanned revascularization (after index admission)
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period. Revascularization is defined as Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting.
The overall number of women and men receiving revascularization
Time frame starts from beginning of index admission, defined as first admission in the study period. Revascularization is defined as Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting.
Number of women with all cause death (after index admission)
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
Number of women with all cause death
Time frame starts from beginning of index admission, defined as first admission in the study period.
Number of men with over-all death (after index admission)
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
Number of men with over-all death
Time frame starts from beginning of index admission, defined as first admission in the study period.
The overall number of women and men with over-all death (after index admission)
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
The overall number of women and men with over-all death
Time frame starts from beginning of index admission, defined as first admission in the study period.
Number of women receiving coronary angiographies or heart CT without revascularization
Time frame starts from beginning of index admission, defined as first admission in the study period.
Number of men receiving coronary angiographies or heart CT without revascularization
Time frame starts from beginning of index admission, defined as first admission in the study period.
The overall number of women and men receiving coronary angiographies or heart CT without revascularization
Time frame starts from beginning of index admission, defined as first admission in the study period.
Number of women receiving treatment with aspirin, dual anti-platelet therapy and/or statins
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
Number of men receiving treatment with aspirin, dual anti-platelet therapy and/or statins
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
The overall number of women and men receiving treatment with aspirin, dual anti-platelet therapy and/or statins
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
Number of women re-admitted
Readmission after index admission
Number of men re-admitted
Readmission after index admission
The overall number of women and men re-admitted
Readmission after index admission
Length of hospital stay for women
Calculated as days from date of index admission to date of discharge
Length of hospital stay for men
Calculated as days from date of index admission to date of discharge
Length of hospital stay for women and men
Calculated as days from date of index admission to date of discharge
The number of women diagnosed with myocardial injury and an event in the primary endpoint
Time frame starts from beginning of index admission, defined as first admission in the study period. The primary endpoint is a composite of myocardial infarction, unplanned revascularisation (after index admission) or all cause mortality within 1 year of index admission.
The number of men diagnosed with myocardial injury and an event in the primary endpoint
Time frame starts from beginning of index admission, defined as first admission in the study period. The primary endpoint is a composite of myocardial infarction, unplanned revascularisation (after index admission) or all cause mortality within 1 year of index admission.
The overall number of men diagnosed with myocardial injury and an event in the primary endpoint
Time frame starts from beginning of index admission, defined as first admission in the study period. The primary endpoint is a composite of myocardial infarction, unplanned revascularisation (after index admission) or all cause mortality within 1 year of index admission.
The number of women diagnosed with myocardial injury
Time frame starts from beginning of index admission, defined as first admission in the study period.
The number of women diagnosed with myocardial injury (after index admission)
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
The number of men diagnosed with myocardial injury
Time frame starts from beginning of index admission, defined as first admission in the study period.
The number of men diagnosed with myocardial injury (after index admission)
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
The overall number of women and men diagnosed with myocardial injury.
Time frame starts from beginning of index admission, defined as first admission in the study period.
The overall number of women and men diagnosed with myocardial injury (after index admission)
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.

Full Information

First Posted
March 29, 2022
Last Updated
October 16, 2023
Sponsor
Herlev Hospital
Collaborators
Rigshospitalet, Denmark, Nordsjaellands Hospital, Amager Hospital, Bispebjerg Hospital, Zealand University Hospital, Slagelse Sygehus, Nykøbing Falster County Hospital, Holbaek Sygehus, Odense University Hospital, Svendborg Hospital, Kolding Sygehus, Aarhus University Hospital, Gødstrup Hospital, Central Jutland Regional Hospital, Randers Regional Hospital, Glostrup University Hospital, Copenhagen, Hvidovre University Hospital, Vejle Hospital, Hospital of Southern Jutland, Horsens Hospital, Aalborg University Hospital, North Denmark Regional Hospital, Sydvestjysk Sygehus, Herlev and Gentofte Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05336435
Brief Title
A Study of Population and Sex-specific Troponin Cutoffs for Ruling Out Acute Myocardial Infarction
Acronym
DANSPOT
Official Title
A Randomized Clinical Trial (RCT) of Population and Sex-specific Troponin Cutoffs for Ruling Out Acute Myocardial Infarction - The Danish Study of Population and Sex-Specific Cutoffs of Troponin
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 1, 2022 (Actual)
Primary Completion Date
February 28, 2025 (Anticipated)
Study Completion Date
February 28, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Herlev Hospital
Collaborators
Rigshospitalet, Denmark, Nordsjaellands Hospital, Amager Hospital, Bispebjerg Hospital, Zealand University Hospital, Slagelse Sygehus, Nykøbing Falster County Hospital, Holbaek Sygehus, Odense University Hospital, Svendborg Hospital, Kolding Sygehus, Aarhus University Hospital, Gødstrup Hospital, Central Jutland Regional Hospital, Randers Regional Hospital, Glostrup University Hospital, Copenhagen, Hvidovre University Hospital, Vejle Hospital, Hospital of Southern Jutland, Horsens Hospital, Aalborg University Hospital, North Denmark Regional Hospital, Sydvestjysk Sygehus, Herlev and Gentofte Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Acute myocardial infarction (MI) is defined as a rise and/or fall in cardiac troponins (cTn) with at least one value above the 99th percentile upper reference limit (URL) in the context of symptoms or clinical evidence of myocardial ischemia. The URL is based on measurements in a healthy reference population. Currently, a sex-uniform manufacturer provided 99th percentile URL of troponin is utilized at Danish hospitals as a diagnostic cutoff for acute MI for both men and women. Reportedly, healthy men have twofold the troponin level compared to healthy women, suggesting that the use of a uniform URL for troponins may lead to the under-diagnostication of acute MI in women and potentially over-diagnostication in men. The purpose of the DANSPOT study is to evaluate the clinical effect on diagnosis, treatment and outcomes in men and women presenting with acute MI of implementing international guidelines recommendations of sex-specific 99th percentile URLs for troponin into clinical practice. First, to determine the sex-specific 99th percentile URLs of troponins based on a healthy Danish reference population, blood samples from Danish blood donors, were analyzed using one troponin T assay and four troponin I assays. Second, the DANSPOT study is a nationwide cluster-randomized trial with "stepped-wedge" design with participation of all 22 Danish hospital laboratories and associated departments of cardiology. With one-month intervals, each of 22 centers are randomized to shift from the presently applied uniform 99th percentile URL of troponin to our newly determined population and sex-specific 99th percentiles URLs. Each patient is followed in Danish registries for 12 months after first admission. The hypothesis of the DANSPOT study is that implementation of population and sex-specific 99th URLs for troponin, will ensure that the right patients receive the right treatment. The investigators expect to detect significantly more women with acute MI, theoretically resulting in a more accurate diagnosis and treatment of women and men with acute MI.
Detailed Description
The present use of non-sex specific diagnostic cut-off levels of troponins in the diagnosis of acute myocardial infarction (MI) leads to under-diagnostication of acute MI in women and over-diagnostication in men. The purpose of this study is to document this through a randomized nationwide clinical implementation of population and sex-specific cut-off levels. Coronary artery disease (CAD) is globally the leading cause of mortality for men and women. The latest consensus statement defines myocardial infarction as 1) a rise and/or fall in cardiac troponins with 2) at least one value above the 99th percentile upper reference limit (URL) in the context of 3) symptoms or clinical evidence of myocardial ischemia. Thus, levels of cardiac troponins play a key role in the diagnostic work-up in general. Currently, uniform manufacturer-provided URLs, defined by the 99th percentile of cardiac troponins in a healthy reference population, is applied in Danish hospitals as a diagnostic cut-off for acute MI for both men and women. Lower levels of cardiac troponins are seen in healthy women as compared to healthy men, i.e. twice as high levels are seen in men. On this basis the clinical use of one uniform 99th percentile URL for cardiac troponins - i.e. applying the same diagnostic levels for men and women - may lead to a systematic under-diagnostication of acute MI in women and potentially an over-diagnostication of acute MI in men. Accordingly, the use of sex-specific 99th percentile URL of cardiac troponins are now recommended in recent guidelines by international cardiological societies, but this remains to be introduced in clinical practice. The 99th percentile URLs for cardiac troponins currently used in Danish Hospitals are provided by the manufacturer of each specific assay based on blood samples from a healthy reference population collected by the manufacturer. Studies have shown that the 99th percentile value is dependent on patient sex as well as on the reference population selected and the definition for "healthy" used in these studies. It is well known that the 99th percentile URL should stem from a local reference population. This recommendation has never been implemented in Denmark. The overall purpose of the study is to evaluate the clinical effect of implementing population and sex-specific 99th percentile URL for cardiac troponins in Denmark. To determine the sex-specific 99th percentile URLs of troponins based on a healthy Danish reference population, blood samples from healthy Danish blood donors, were analyzed using one troponin T assay and four troponin I assays. Second, the DANSPOT study is a nationwide cluster-randomized trial with "stepped-wedge" design with participation of all 22 Danish hospital laboratories and associated departments of cardiology. With one-month intervals, each of 22 centers are randomized to shift from the presently applied uniform 99th percentile URL of troponin to our newly determined population and sex-specific 99th percentiles URLs. Each patient is followed in Danish registries for 12 months after first admission. The clinical significance of sex-specific 99th percentile URLs of troponin is poorly investigated and for the same reason not yet implemented in Denmark or many other countries. The basic hypothesis of the DANSPOT study is that the implementation of population and sex-specific 99th URLs for troponin, will ensure that the right patients receive the right treatment. The investigators expect to detect significantly more women with acute MI, theoretically resulting in a more accurate diagnosis and treatment of women and men with acute MI. This would be guideline-defining for implementing sex-specific cutoffs for cardiac troponin in Denmark as well as internationally as recommended in guidelines by professional cardiological societies.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Syndrome, Acute, Coronary Artery Disease, Myocardial Infarction
Keywords
coronary syndrome, myocardial infarction, clinical assessment, biomarker, troponin

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
A nationwide cluster-randomized trial with "stepped-wedge" design
Masking
Outcomes Assessor
Masking Description
A diagnosis of acute MI will be adjudicated for all individuals in the primary cohort by an endpoint committee consisting of three cardiologists from another region in Denmark.
Allocation
Randomized
Enrollment
7500 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control Arm - Current sex-uniform manufacturer provided 99th percentile URL of troponin
Arm Type
No Intervention
Arm Description
Standard use of the current sex-uniform manufacturer provided 99th percentile URL of troponin is utilized at Danish hospitals as a diagnostic cutoff for acute MI for both men and women
Arm Title
Intervention Arm - New population and sex-specific 99th percentile URLs of troponin
Arm Type
Active Comparator
Arm Description
Implementation of the new population and sex-specific 99th percentile URLs of troponin for the specific assay utilized at the enrolled centers.
Intervention Type
Diagnostic Test
Intervention Name(s)
Implementation of the new population and sex-specific 99th percentile URL for cardiac troponin
Intervention Description
The new population and sex-specific 99th percentiles URLs will be implemented at all Danish hospitals receiving patients with chest pain for initial diagnostics for possible acute MI. This will take place as a randomized step-by-step introduction of population and sex-specific 99th percentile URLs for troponin in all hospital centers with a monthly start time interval. Each center is randomized to shifting from the sex-uniform manufacturer provided 99th percentile URL of cardiac troponin currently used nationwide to the new population and sex-specific 99th percentiles URLs provided by the DANSPOT study's first phase.
Primary Outcome Measure Information:
Title
A composite of myocardial infarction, unplanned revascularisation (after index admission) or all cause mortality within 1 year of first admission for the primary cohort.
Description
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period. Primary cohort is defined as the cohort of women and men with suspected acute coronary syndrome (ACS) with at least two cTn measurements within 24 hours with a maximal cTn level between the current sex-uniform manufacturer-derived 99th percentiles of cTn and the newly defined sex-specific 99th percentiles for women and men.
Time Frame
12 months after index admission
Secondary Outcome Measure Information:
Title
Number of women with coronary events in the primary cohort (after index admission)
Description
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period. Primary cohort is defined as the cohort of women and men with suspected acute coronary syndrome (ACS) with at least two cTn measurements within 24 hours with a maximal cTn level between the current sex-uniform manufacturer-derived 99th percentiles of cTn and the newly defined sex-specific 99th percentiles for women and men. Coronary events are defined as the prevalence of cardiovascular death, myocardial infarction or unplanned revascularisation (after index admission) within 1 year of first admission.
Time Frame
12 months after index admission
Title
Number of men with coronary events in the primary cohort (after index admission)
Description
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period. Primary cohort is defined as the cohort of women and men with suspected acute coronary syndrome (ACS) with at least two cTn measurements within 24 hours with a maximal cTn level between the current sex-uniform manufacturer-derived 99th percentiles of cTn and the newly defined sex-specific 99th percentiles for women and men. Coronary events are defined as the prevalence of cardiovascular death, myocardial infarction or unplanned revascularisation (after index admission) within 1 year of first admission.
Time Frame
12 months after index admission
Title
Number of women and men with coronary events in the primary cohort (after index admission)
Description
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period. Primary cohort is defined as the cohort of women and men with suspected acute coronary syndrome (ACS) with at least two cTn measurements within 24 hours with a maximal cTn level between the current sex-uniform manufacturer-derived 99th percentiles of cTn and the newly defined sex-specific 99th percentiles for women and men. Coronary events are defined as the prevalence of cardiovascular death, myocardial infarction or unplanned revascularisation (after index admission) within 1 year of first admission.
Time Frame
12 months after index admission
Title
Number of women diagnosed with acute MI (after index admission)
Description
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
Time Frame
12 months after index admission
Title
Number of women diagnosed with acute MI
Description
Time frame starts from beginning of index admission, defined as first admission in the study period.
Time Frame
12 months from index admission
Title
Number of men diagnosed with acute MI (after index admission)
Description
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
Time Frame
12 months after index admission
Title
Number of men diagnosed with acute MI
Description
Time frame starts from beginning of index admission, defined as first admission in the study period.
Time Frame
12 months from index admission
Title
The overall number of women and men diagnosed with acute MI (after index admission)
Description
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
Time Frame
12 months after index admission
Title
The overall number of women and men diagnosed with acute MI
Description
Time frame starts from beginning of index admission, defined as first admission in the study period.
Time Frame
12 months from index admission
Title
Number of women receiving unplanned revascularization (after index admission)
Description
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period. Revascularization is defined as Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting.
Time Frame
12 months after index admission
Title
Number of women receiving revascularization
Description
Time frame starts from beginning of index admission, defined as first admission in the study period. Revascularization is defined as Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting.
Time Frame
12 months from index admission
Title
Number of men receiving unplanned revascularization (after index admission)
Description
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period. Revascularization is defined as Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting.
Time Frame
12 months after index admission
Title
Number of men receiving revascularization
Description
Time frame starts from beginning of index admission, defined as first admission in the study period. Revascularization is defined as Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting.
Time Frame
12 months from index admission
Title
The overall number of women and men receiving unplanned revascularization (after index admission)
Description
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period. Revascularization is defined as Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting.
Time Frame
12 months after index admission
Title
The overall number of women and men receiving revascularization
Description
Time frame starts from beginning of index admission, defined as first admission in the study period. Revascularization is defined as Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting.
Time Frame
12 months from index admission
Title
Number of women with all cause death (after index admission)
Description
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
Time Frame
12 months after index admission
Title
Number of women with all cause death
Description
Time frame starts from beginning of index admission, defined as first admission in the study period.
Time Frame
12 months from index admission
Title
Number of men with over-all death (after index admission)
Description
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
Time Frame
12 months after index admission
Title
Number of men with over-all death
Description
Time frame starts from beginning of index admission, defined as first admission in the study period.
Time Frame
12 months from index admission
Title
The overall number of women and men with over-all death (after index admission)
Description
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
Time Frame
12 months after index admission
Title
The overall number of women and men with over-all death
Description
Time frame starts from beginning of index admission, defined as first admission in the study period.
Time Frame
12 months from index admission
Title
Number of women receiving coronary angiographies or heart CT without revascularization
Description
Time frame starts from beginning of index admission, defined as first admission in the study period.
Time Frame
12 months from index admission
Title
Number of men receiving coronary angiographies or heart CT without revascularization
Description
Time frame starts from beginning of index admission, defined as first admission in the study period.
Time Frame
12 months from index admission
Title
The overall number of women and men receiving coronary angiographies or heart CT without revascularization
Description
Time frame starts from beginning of index admission, defined as first admission in the study period.
Time Frame
12 months from index admission
Title
Number of women receiving treatment with aspirin, dual anti-platelet therapy and/or statins
Description
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
Time Frame
12 months after index admission
Title
Number of men receiving treatment with aspirin, dual anti-platelet therapy and/or statins
Description
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
Time Frame
12 months after index admission
Title
The overall number of women and men receiving treatment with aspirin, dual anti-platelet therapy and/or statins
Description
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
Time Frame
12 months after index admission
Title
Number of women re-admitted
Description
Readmission after index admission
Time Frame
12 months after index admission
Title
Number of men re-admitted
Description
Readmission after index admission
Time Frame
12 months after index admission
Title
The overall number of women and men re-admitted
Description
Readmission after index admission
Time Frame
12 months after index admission
Title
Length of hospital stay for women
Description
Calculated as days from date of index admission to date of discharge
Time Frame
30 days
Title
Length of hospital stay for men
Description
Calculated as days from date of index admission to date of discharge
Time Frame
30 days
Title
Length of hospital stay for women and men
Description
Calculated as days from date of index admission to date of discharge
Time Frame
30 days
Title
The number of women diagnosed with myocardial injury and an event in the primary endpoint
Description
Time frame starts from beginning of index admission, defined as first admission in the study period. The primary endpoint is a composite of myocardial infarction, unplanned revascularisation (after index admission) or all cause mortality within 1 year of index admission.
Time Frame
12 months from index admission
Title
The number of men diagnosed with myocardial injury and an event in the primary endpoint
Description
Time frame starts from beginning of index admission, defined as first admission in the study period. The primary endpoint is a composite of myocardial infarction, unplanned revascularisation (after index admission) or all cause mortality within 1 year of index admission.
Time Frame
12 months from index admission
Title
The overall number of men diagnosed with myocardial injury and an event in the primary endpoint
Description
Time frame starts from beginning of index admission, defined as first admission in the study period. The primary endpoint is a composite of myocardial infarction, unplanned revascularisation (after index admission) or all cause mortality within 1 year of index admission.
Time Frame
12 months from index admission
Title
The number of women diagnosed with myocardial injury
Description
Time frame starts from beginning of index admission, defined as first admission in the study period.
Time Frame
12 months from index admission
Title
The number of women diagnosed with myocardial injury (after index admission)
Description
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
Time Frame
12 months after index admission
Title
The number of men diagnosed with myocardial injury
Description
Time frame starts from beginning of index admission, defined as first admission in the study period.
Time Frame
12 months from index admission
Title
The number of men diagnosed with myocardial injury (after index admission)
Description
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
Time Frame
12 months after index admission
Title
The overall number of women and men diagnosed with myocardial injury.
Description
Time frame starts from beginning of index admission, defined as first admission in the study period.
Time Frame
12 months from index admission
Title
The overall number of women and men diagnosed with myocardial injury (after index admission)
Description
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
Time Frame
12 months after index admission

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria for the primary cohort: The primary cohort will include the women and men who are expected to be most significantly impacted by the intervention, and this group is specifically defined by Presenting complaints suggestive of ACS At least one cTn measurement within 24 hours of admission A peak cTn value between the current sex-uniform manufacturer-derived 99th percentile URL and the novel sex-and population-specific 99th percentile URLs for women and men. Presenting complaints suggestive of ACS will be identified in hospital records by the following presenting complaints of "chest pain" (DR074), "angina pectoris" (DI20) and "myocardial infarction" (DI21), "abdominal and pelvic pain" (DR10), "pain in the throat and chest" (DR07), "dyspnea" (DR060), "reflux" (DK21) and "observation due to suspicion of another cardiovascular disorder" (DZ035). Study participants are included at their index admission, and subsequent admissions are evaluated in follow up analyses. Exclusion criteria: Age < 18 years Patients with discharge diagnoses with conditions like pericarditis, myocarditis, endocarditis, cardiomyopathy, valve disease, arrhythmia, heart failure, pulmonary embolism, digestive system diseases, diseases of the urinary and reproductive organs, and diseases of bones, muscles, and connective tissue, and no discharge diagnosis of myocardial infarction or angina pectoris The initial month following the implementation of the new sex-specific 99th percentile URLs will be excluded from consideration, as it will be seen as an adjustment period. Consequently, the intervention period will be extended by one month.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kasper K Iversen, MD, DMsc
Phone
38686009
Email
Kasper.Karmark.Iversen@regionh.dk
First Name & Middle Initial & Last Name or Official Title & Degree
Christian Torp-Pedersen, MD, DMsc
Email
christian.torp-pedersen.01@regionh.dk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kasper K Iversen, MD, DMsc
Organizational Affiliation
Herlev Hospital, University Hospital of Copenhagen
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital of Southern Jutland
City
Aabenraa
ZIP/Postal Code
6200
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rasmus Albiniussen, MD
Email
Rasmus.Albiniussen2@rsyd.dk
Facility Name
Aalborg University Hospital
City
Aalborg
ZIP/Postal Code
9000
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin K Christensen, MD
Email
m.kirk@rn.dk
Facility Name
Aarhus University Hospital
City
Aarhus
ZIP/Postal Code
8000
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christian J Terkelsen, MD, DMSc
Email
christian.terkelsen@skejby.rm.dk
Facility Name
Bispebjerg & Frederiksberg Hospital
City
Bispebjerg
ZIP/Postal Code
2400
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ida Gustafsson, MD, PhD
Email
ida.gustafsson@regionh.dk
Facility Name
Rigshospitalet (Blegdamsvej)
City
Copenhagen Ø
ZIP/Postal Code
2100
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lene Holmvang, MD, DMSc
Email
Lene.Holmvang@regionh.dk
Facility Name
Sydvestjysk Sygehus
City
Esbjerg
ZIP/Postal Code
6700
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Monija M Hansen, MD
Email
momrg@hotmail.com
Facility Name
Glostrup University Hospital
City
Glostrup
ZIP/Postal Code
2600
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Britt Falskov, MD, PhD
Email
britt.falskov.01@regionh.dk
Facility Name
Gødstrup Regional Hospital
City
Gødstrup
ZIP/Postal Code
7400
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Morten Bøttcher, MD, PhD
Email
morboett@rm.dk
Facility Name
Herlev & Gentofte Hospital
City
Herlev
ZIP/Postal Code
2730
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kasper K Iversen, MD, DMsc
Email
Kasper.Karmark.Iversen@regionh.dk
First Name & Middle Initial & Last Name & Degree
Nina Strandkjær, MD
Phone
+4527207681
Email
nina.strandkjaer.01@regionh.dk
Facility Name
C Torp-Pedersen
City
Hillerød
ZIP/Postal Code
3400
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
C Torp-Pedersen, MD, DMsc
Email
ctp@sund.ku.dk
Facility Name
North Denmark Regional Hospital
City
Hjørring
ZIP/Postal Code
9800
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peter B Stæhr, MD, PhD
Email
p.staehr@rn.dk
Facility Name
Holbaek Sygehus
City
Holbæk
ZIP/Postal Code
4300
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Micheael H Olsen, MD,DMSc
Email
miheo@regionsjaelland.dk
Facility Name
Horsens Hospital
City
Horsens
ZIP/Postal Code
8700
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Karen K Dodt, MD, PhD
Email
dodt@horsens.rm.dk
Facility Name
Amager & Hvidovre Hospital
City
Hvidovre
ZIP/Postal Code
2650
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Magnus T Jensen, MD, DMSc
Email
magnus.thorsten.jensen@regionh.dk
Facility Name
Sygehus Lillebælt (Kolding Sygehus & Vejle Sygehus)
City
Kolding
ZIP/Postal Code
6000
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jonas Sjøland, MD, PhD
Email
Jonas.Angel.Sjoland@rsyd.dk
First Name & Middle Initial & Last Name & Degree
Sejr L Horskjær, MD
Email
Sejr.Lykke.Horskjaer@rsyd.dk
Facility Name
Zealand University Hospital
City
Køge
ZIP/Postal Code
4600
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Niels E Bruun, MD, DMSc
Email
nbru@regionsjaelland.dk
Facility Name
Nykøbing Falster County Hospital
City
Nykøbing Falster
ZIP/Postal Code
4800
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peer Grande, MD, Dmsc
Email
pgra@regionsjaelland.dk
Facility Name
Odense University Hospital
City
Odense
ZIP/Postal Code
5000
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gro Egholm, MD
Email
gro.egholm@rsyd.dk
Facility Name
Randers Regional Hospital
City
Randers
ZIP/Postal Code
8930
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bo Løfgren, MD, PhD
Email
bo.loefgren@rm.dk
Facility Name
Slagelse Sygehus
City
Slagelse
ZIP/Postal Code
4200
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Henrik Ryde, MD
Email
hry@regionsjaelland.dk
Facility Name
Svendborg Hospital
City
Svendborg
ZIP/Postal Code
5700
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jess Lambrechtsen, MD, PhD
Email
jess.lambrechtesen@rsyd.dk
Facility Name
Central Jutland Regional Hospital (Viborg Hospital & Silkeborg Hospital)
City
Viborg
ZIP/Postal Code
8800
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hanne M Søndergaard, MD, PhD
Email
hanne.soendergaard@viborg.rm.dk
First Name & Middle Initial & Last Name & Degree
Lene H Madsen, MD, PhD
Email
lenhelma@rm.dk

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

A Study of Population and Sex-specific Troponin Cutoffs for Ruling Out Acute Myocardial Infarction

We'll reach out to this number within 24 hrs